65,437 trials
Spasticity · Multiple Sclerosis
Primary: The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B). — 3.68; 4.56 Points on scale — p=0.0002
Anaplastic Large Cell Lymphoma · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Primary: Proportion of Participants With Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment…
Postoperative Nausea and Vomiting
Primary: Number of Participants Having Post-operative Emesis and Nausea. — 7; 22 participants — p=<0.05
Human Volunteer
Primary: Mean Percent Change From Screening in Sperm Concentration. — 9.8; -1.3 Percent change
Head and Neck Cancer
Primary: Patient Response — 11; 15; 6; 0 participants
Coronary Artery Disease · Cardiovascular Diseases
Primary: Composite Endpoint of Cardiac Death and Myocardial Infarction (Not Clearly Attributable to a Non-target Vessel) — 4.2 percentage of participants
Osteoarthritis
Primary: Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline — -44.1; -43.6; -37.3 mm
Vascular Closure
Primary: Mean Score on the Visual Analogue Scale — 0.63; 0.59; 2.94; 5.03 Scores on a Scale
Chalazion · Dry Eye Syndromes
Primary: Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) — 0.4816 Correlation coefficient…
Thrombosis · Heparin-induced Thrombocytopenia
Primary: Number of Abnormal Lab Results Resulting in Adverse Events. — 0 Adverse Events
Breast Cancer · Fatigue · Hot Flashes
Primary: The Difference in Hot Flash Score (Frequency and Severity) Between Baseline (Week 1) and Week 9 — -6.5; -7.5; -6.5 units on a scale — p=0.3679
Diabetes
Primary: Insulin Secretion at 150-180 Minutes. — 104; 94; 81; 92 10^-9 min^-1 — p=0.11
Lupus Nephritis
Primary: Induction Phase: Number of Patients Showing Treatment Response — 98; 104; 87; 81 participants — p=0.478
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
Pre-diabetes
Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05